Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Dash Solutions has introduced dashClinical, a payment solution that provides real-time, secure payments to clinical trial ...

BridgeBio’s stock was up after it announced the Phase III trial met its endpoints. Image credit: saepul_bahri / Shutterstock.com. BridgeBio Pharma will seek US approval of its limb-girdle muscular ...

The data was announced during the 2025 North American Menopause Society (NAMS) Annual Meeting. Image credit: shisu_ka / Shutterstock.com. Entera Bio’s osteoporosis candidate for postmenopausal women ...

Inhibrx’s DR5-targeting antibody has more than doubled PFS compared with placebo in a Phase II trial in chondrosarcoma, a rare bone cancer with no approved targeted therapies. Image credit: Kateryna ...

Medtronic plans to use data from the ADAPT-PD trial to support the Percept PC’s aDBS global regulatory filing. Image credit: JHVEPhoto / Shutterstock. Medtronic has published preliminary data from a ...

Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli Lilly’s Zepbound (tirzepatide) in a ...